Lataa...
Antifibrotics in COVID-19 Lung Disease: Let Us Stay Focused
After decades of research, two therapies for chronic fibrotic lung disease are now approved by the FDA, with dozens more anti-fibrotic therapies in the pipeline. A great deal of enthusiasm has been generated for the use of these drugs, which are by no means curative but clearly have a favorable impa...
Tallennettuna:
| Julkaisussa: | Front Med (Lausanne) |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Frontiers Media S.A.
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7531602/ https://ncbi.nlm.nih.gov/pubmed/33072773 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fmed.2020.00539 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|